A new era in cancer
By Andrew Powaleny | November 1, 2017
The last few years have seen unparalleled progress in cancer care, with breakthrough research driving major advances in diagnosis and treatment. Next week, on Wednesday, November 8, leading minds...
Read More
PhRMA, member companies and NIH create public-private partnership for immuno-oncology
By Andrew Powaleny | October 12, 2017
The rapid pace of scientific advances has helped usher in a new era of medicine for cancer patients over the last decade. This morning, the National Institutes of Health (NIH) took a significant...
Read More
What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace
By Holly Campbell | September 12, 2017
This post has been updated as of 10/2/2017 A recent study published in JAMA Internal Medicine provides flawed and inaccurate estimates of the significant research and development (R&D) investments...
Read More
Protect your health: Important disaster preparedness tips for Harvey and Irma
By Guest Contributor | September 6, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
By Nicole Longo | June 12, 2017
We’ve seen significant progress in recent years in the treatment of cancer, and that progress is expected to continue. A new report released this month found that there are more than 240 new...
Read More
More than 240 immuno-oncology treatments in development to fight cancer
By Andrew Powaleny | June 1, 2017
The American Cancer Society estimates that in 2017 alone, there will be more than 1.6 million new cases of cancer and 600,000 cancer deaths in the United States. With estimates like these, the...
Read More
Medicines have significantly increased chances of cancer survival around the globe
By Amey Sutkowski | May 24, 2017
Since a peak in 1991, cancer mortality rates have declined by as much as 27% around the world. These gains in cancer survival are largely attributed to new and innovative therapies. According to...
Read More
ICYMI: Report highlights overall decrease in cancer death rates
By Andrew Powaleny | April 3, 2017
In case you missed it, cancer death rates are continuing to decrease for men, women and children in the United States thanks in part to biopharmaceutical innovation, according to the Annual Report...
Read More
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
By Robert Zirkelbach | February 5, 2017
Today, as part of our new advertising and public affairs initiative, GOBOLDLY™, we are excited to announce the premier of our newest TV advertisement, Cells, which highlights innovative...
Read More
The 20-year journey yielding a new weapon against cancer
By Andrew Powaleny | January 10, 2017
Developing new medicines is a long, complex process. On average, it takes at least 10-12 years for a new medicine to complete the journey from initial discovery to becoming part of a patient’s...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
